Document is current
Any future updates will be listed below
-
Authors
Takahashi, Nobuyuki
Pongor, Lorinc
Agrawal, Shivam P.
Shtumpf, Mariya
Gurjar, Ankita
Rajapakse, Vinodh N.
Shafiei, Ahmad
Schultz, Christopher W.
Kim, Sehyun
Roame, Diana
Carter, Paula
Vilimas, Rasa
Nichols, Samantha
Desai, Parth
Figg, William Douglas
Bagheri, Mohammad
Teif, Vladimir B.
Thomas, Anish https://orcid.org/0000-0003-3293-3115
-
Funding
Funding for this research was provided by:
National Cancer Institute
- License Information
-
More Information
Article History
Received: 17 September 2023
Accepted: 11 February 2025
First Online: 25 February 2025
Declarations
:
: The trial was conducted under a NCI Center for Cancer Research–sponsored investigational new drug application with institutional review board approval (15-c-0145). Written informed consent was obtained from all patients as well as to use and share data and specimens collected for the study. The study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.
: Informed consent for publication was obtained from the patients who participated in the study.
: AT reports research funding from AstraZeneca, Tarveda, EMD Serono, and Prolynx. The remaining authors declare that they have no competing interests.
